Derma Sciences Inc. (NASDAQ:DSCI) has been assigned an average recommendation of “Hold” from the six ratings firms that are presently covering the firm. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.00.
DSCI has been the subject of a number of analyst reports. Zacks Investment Research lowered Derma Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 11th. TheStreet upgraded Derma Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, August 9th.
Shares of Derma Sciences (NASDAQ:DSCI) traded up 0.543% during mid-day trading on Tuesday, reaching $4.625. The company’s stock had a trading volume of 22,349 shares. Derma Sciences has a 52-week low of $2.85 and a 52-week high of $5.99. The firm’s 50 day moving average is $4.68 and its 200-day moving average is $4.24. The company’s market capitalization is $130.91 million.
Derma Sciences (NASDAQ:DSCI) last announced its quarterly earnings results on Tuesday, August 9th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.16. Derma Sciences had a negative return on equity of 11.74% and a negative net margin of 21.19%. The company earned $22.20 million during the quarter, compared to analyst estimates of $22.40 million. Analysts forecast that Derma Sciences will post ($0.04) EPS for the current year.
Hedge funds have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. raised its stake in shares of Derma Sciences by 170.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 117,271 shares of the company’s stock valued at $364,000 after buying an additional 73,911 shares during the period. Franklin Resources Inc. raised its stake in shares of Derma Sciences by 2.5% in the first quarter. Franklin Resources Inc. now owns 2,684,500 shares of the company’s stock worth $8,322,000 after buying an additional 65,192 shares during the period. Emerald Acquisition Ltd. bought a new stake in shares of Derma Sciences during the second quarter worth about $202,000. Granahan Investment Management Inc. MA raised its stake in shares of Derma Sciences by 5.1% in the first quarter. Granahan Investment Management Inc. MA now owns 1,028,460 shares of the company’s stock worth $3,188,000 after buying an additional 50,142 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Derma Sciences by 1.1% in the second quarter. Vanguard Group Inc. now owns 802,878 shares of the company’s stock worth $3,163,000 after buying an additional 8,376 shares during the period. Institutional investors and hedge funds own 62.44% of the company’s stock.
Derma Sciences Company Profile
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
Receive News & Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.